Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children,” published in the November 2024 ...

In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute ...

The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.

The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...

RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...